GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » EPS (Diluted)

Palisade Bio (Palisade Bio) EPS (Diluted) : $-23.64 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio EPS (Diluted)?

Palisade Bio's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-4.59. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.64.

Palisade Bio's EPS (Basic) for the three months ended in Mar. 2024 was $-4.59. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.64.

Palisade Bio's EPS without NRI for the three months ended in Mar. 2024 was $-4.59. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Palisade Bio EPS (Diluted) Historical Data

The historical data trend for Palisade Bio's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio EPS (Diluted) Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-2,790.00 -2,546.10 -247.95 -27.00

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.13 -7.95 -7.35 -3.75 -4.59

Competitive Comparison of Palisade Bio's EPS (Diluted)

For the Biotechnology subindustry, Palisade Bio's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palisade Bio's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's PE Ratio distribution charts can be found below:

* The bar in red indicates where Palisade Bio's PE Ratio falls into.



Palisade Bio EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Palisade Bio's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-12.3-0)/0.456
=-26.97

Palisade Bio's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.527-0)/0.768
=-4.59

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palisade Bio  (NAS:PALI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Palisade Bio EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Palisade Bio's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Palisade Bio (Palisade Bio) Business Description

Traded in Other Exchanges
Address
5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Executives
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley officer: Chief Financial Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones officer: Chief Medical Officer 70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae officer: Chief Operating Officer 675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam director, officer: Chief Executive Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson officer: Chief Medical Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center 10 percent owner 2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei director P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter director, officer: Executive Chairman 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma director 14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142